UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

The New England journal of medicine, 2018-08, Vol.379 (9), p.811-822

2018

Volltextzugriff (PDF)

Low immunogenicity of emicizumab in persons with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-11, Vol.27 (6), p.984-992

2021

Volltextzugriff (PDF)

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-11, Vol.28 (6), p.1033-1043

2022

Volltextzugriff (PDF)

Determining meaningful health‐related quality‐of‐life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL)

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-11, Vol.26 (6), p.1019-1030

2020

Volltextzugriff (PDF)

Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study

British journal of haematology, 2022-08, Vol.198 (3), p.e46-e50

2022

Volltextzugriff (PDF)

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-09, Vol.27 (5), p.854-865

2021

Volltextzugriff (PDF)

Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays

International journal of laboratory hematology, 2020-04, Vol.42 (2), p.e71-e75

2020

Volltextzugriff (PDF)

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-11, Vol.27 (6), p.e772-e775

2021

Volltextzugriff (PDF)

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-03, Vol.27 (2), p.221-228

2021

Volltextzugriff (PDF)

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

Scientific reports, 2023-06, Vol.13 (1), p.10078-10078, Article 10078

2023

Volltextzugriff (PDF)

Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors

Clinical pharmacology and therapeutics, 2023-04, Vol.113 (4), p.904-915

2023

Volltextzugriff (PDF)

Loss of IKKβ but Not NF-κB p65 Skews Differentiation towards Myeloid over Erythroid Commitment and Increases Myeloid Progenitor Self-Renewal and Functional Long-Term Hematopoietic Stem Cells

PloS one, 2015-06, Vol.10 (6), p.e0130441-e0130441

2015

Volltextzugriff (PDF)

Cyclophosphamide for Rapid-Onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome

The Journal of pediatrics, 2011-02, Vol.158 (2), p.337-339

2011

Volltextzugriff (PDF)

Thromboembolic Events in Children and Young Adults With Pediatric Sarcoma

Journal of clinical oncology, 2007-04, Vol.25 (12), p.1519-1524

2007

Volltextzugriff (PDF)

A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology

PloS one, 2013-11, Vol.8 (11), p.e79950-e79950

2013

Volltextzugriff (PDF)

Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphoma

Pediatric blood & cancer, 2014-07, Vol.61 (7), p.1210-1214

2014

Volltextzugriff (PDF)

CCAAT/Enhancer Binding Protein α (C/EBPα) and C/EBPα Myeloid Oncoproteins Induce Bcl-2 via Interaction of Their Basic Regions with Nuclear Factor-κB p50

Molecular cancer research, 2005-10, Vol.3 (10), p.585-596

2005

Volltextzugriff (PDF)

CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells

Oncogene, 2015-11, Vol.34 (48), p.5912-5922

2015

Volltextzugriff (PDF)

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

Thrombosis and haemostasis, 2019-07, Vol.119 (7), p.1084-1093

2019

Volltextzugriff (PDF)

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Blood, 2021-04, Vol.137 (16), p.2231-2242

2021

Volltextzugriff (PDF)

Crovalimab for Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Complement C5 Polymorphism - Experience from the Phase I/II COMPOSER Study

Blood, 2020-11, Vol.136 (Supplement 1), p.5-6

2020

Volltextzugriff (PDF)

Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial

Current medical research and opinion, 2019-12, Vol.35 (12), p.2079-2087

2019

Volltextzugriff (PDF)

C/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion

Cancer letters, 2016-05, Vol.375 (1), p.152-161

2016

Volltextzugriff (PDF)

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

Blood, 2018-11, Vol.132 (Supplement 1), p.633-633

2018

Volltextzugriff (PDF)

C/EBPα binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment

Blood, 2007-11, Vol.110 (9), p.3136-3142

2007

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(62)

Sprache

Englisch
(62)

Erscheinungsjahr

n.n

Thema

Science & Technology
(29)
Life Sciences & Biomedicine
(26)
Humans
(24)
Hematology
(14)
Animals
(9)
Hemophilia A - Drug Therapy
(9)
Hemophilia
(8)
Mice
(8)
Emicizumab
(7)
Oncology
(7)
Adult
(6)
Coagulation Factors
(6)
Male
(6)
Prophylaxis
(6)
Female
(5)
Haemophilia A
(5)
Mice, Transgenic
(5)
Antibodies, Bispecific - Pharmacology
(4)
Antibodies, Bispecific - Therapeutic Use
(4)
Biological And Medical Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Low immunogenicity of emicizumab in persons with haemophilia A

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

Determining meaningful health‐related quality‐of‐life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem‐A‐QoL)

Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors

Loss of IKKβ but Not NF-κB p65 Skews Differentiation towards Myeloid over Erythroid Commitment and Increases Myeloid Progenitor Self-Renewal and Functional Long-Term Hematopoietic Stem Cells

Cyclophosphamide for Rapid-Onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome

Thromboembolic Events in Children and Young Adults With Pediatric Sarcoma

A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology

Patterns of failure after involved field radiation therapy for pediatric and young adult Hodgkin lymphoma

CCAAT/Enhancer Binding Protein α (C/EBPα) and C/EBPα Myeloid Oncoproteins Induce Bcl-2 via Interaction of Their Basic Regions with Nuclear Factor-κB p50

CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Crovalimab for Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria and Complement C5 Polymorphism - Experience from the Phase I/II COMPOSER Study

Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial

C/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

C/EBPα binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment

Suchergebnisse filtern